Drug class profile · refreshed daily from federal data

Cytochrome P450 17A1 Inhibitor

1 molecule in this class, $1.02B combined CY2024 Part D spend across 612K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Cytochrome P450 17A1 Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
1tracked in Part D
CY24 Part D spend
$1.02Bcombined across class
Total Rx claims
612K105K unique beneficiaries
Generic mfrs (active)
12across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Abiraterone
Brand: Abiraterone · 612K Part D claims (CY24) · 105K beneficiaries · First FDA approval:
12 generic mfrs 942 plans require PA
Low NADAC$0.831
Avg plan cost$1.60
Part D spend $1.02B spread, current vs floor
Class share
100%
of class CY24 spend
View profile →